Display options
Cite
Tzogani K, Hennik PV, Walsh I, et al. EMA Review of Panobinostat (Farydak) for the Treatment of Adult Patients with Relapsed and/or Refractory Multiple Myeloma. Oncologist. 2018;23(7):870doi: 10.1634/theoncologist.2017-0301erratum.
Tzogani, K., Hennik, P. V., Walsh, I., De Graeff, P., Folin, A., Sjöberg, J., Salmonson, T., Bergh, J., Laane, E., Ludwig, H., Gisselbrecht, C., & Pignatti, F. (2018). EMA Review of Panobinostat (Farydak) for the Treatment of Adult Patients with Relapsed and/or Refractory Multiple Myeloma. The oncologist, 23(7), 870. https://doi.org/10.1634/theoncologist.2017-0301erratum
Tzogani, Kyriaki, et al. "EMA Review of Panobinostat (Farydak) for the Treatment of Adult Patients with Relapsed and/or Refractory Multiple Myeloma." The oncologist vol. 23,7 (2018): 870. doi: https://doi.org/10.1634/theoncologist.2017-0301erratum
Tzogani K, Hennik PV, Walsh I, De Graeff P, Folin A, Sjöberg J, Salmonson T, Bergh J, Laane E, Ludwig H, Gisselbrecht C, Pignatti F. EMA Review of Panobinostat (Farydak) for the Treatment of Adult Patients with Relapsed and/or Refractory Multiple Myeloma. Oncologist. 2018 Jul;23(7):870. doi: 10.1634/theoncologist.2017-0301erratum. PMID: 30037941; PMCID: PMC6058342.
Copy Download .nbib Format: NLM
Share it on

Oncologist. 2018 Jul;23(7):870. doi: 10.1634/theoncologist.2017-0301erratum.

EMA Review of Panobinostat (Farydak) for the Treatment of Adult Patients with Relapsed and/or Refractory Multiple Myeloma.

The oncologist

Kyriaki Tzogani, Paula Van Hennik, Ita Walsh, Pieter De Graeff, Annika Folin, Jan Sjöberg, Tomas Salmonson, Jonas Bergh, Edward Laane, Heinz Ludwig, Christian Gisselbrecht, Francesco Pignatti

PMID: 30037941 PMCID: PMC6058342 DOI: 10.1634/theoncologist.2017-0301erratum

[No abstract available.]

Publication Types